Page 1

SOLID BIOSCIENCES Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates August 6 , 2026 - Duchenne ( SGT - 003 ) : SGT - 003 has been generally well tolerated in the Phase 1/2 INSPIRE DUCHENNE clinical trial , with 53 participants dosed as of August 4 , 2026- - Solid expects to meet with the FDA in late Q4 2026 to discuss the SGT - 003 data package and to seek guidance on a potential accelerated approval pathway for SGT - 003- - Initiation of dosing in the Phase 3 IMPACT DUCHENNE placebo - controlled , randomized , double - blind clinical trial commenced in Q2 2026 - - Friedreich's Ataxia ( SGT - 212 ) : Continued participant screening and enrollment is underway in the Phase 1b FALCON clinical trial ; SGT - 212 has been well tolerated in the two participants dosed as of August 4 , 2026 - - Capital Position : Cash , cash equivalents and available - for - sale securities of $ 377.7 million at June 30 , 2026 ; the Company's cash runway is anticipated to support late - stage development and early pipeline opportunities into mid - 2028 - CHARLESTOWN , Mass . , Aug. 06 , 2026 ( GLOBE NEWSWIRE ) -- Solid Biosciences Inc. ( Nasdaq : SLDB ) ( the " Company " or " Solid " ) , a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases , today reported financial results for the second quarter ended June 30 , 2026 , and provided a business update . Bo Cumbo , President and CEO of Solid Biosciences , stated : " Our progress in the first half of 2026 positions us for continued momentum as we approach multiple key clinical and regulatory milestones across our Duchenne , Friedreich's ataxia and broader precision genetic medicine platform over the next several quarters . In Duchenne , we continue to have confidence in SGT - 003's safety profile , which is achieved using a low - burden , steroid - only immunomodulation regimen . We are also highly encouraged by the strength of the biomarker data we have generated to date , which demonstrates promising biologic activity . As we prepare to analyze 12 - month clinical data from initial participants in the INSPIRE DUCHENNE trial , we gain an important opportunity to evaluate the relationship between these biologic signals and clinical outcomes . We look forward to continued engagement with the FDA as we work with urgency to evaluate a potential accelerated approval pathway for SGT - 003 . " Mr. Cumbo continued , “ In FA , we continue to progress SGT - 212 with two participants dosed in the FALCON clinical trial , and we look forward to sharing initial data in the first quarter of 2027 , which will help inform future development pathways as we aim to bring SGT - 212 rapidly to the FA patient community . " Company Updates Neuromuscular Pipeline SGT - 003 Next - Generation Duchenne Muscular Dystrophy ( Duchenne ) Program • SGT - 003 has been well tolerated in the 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of August 4 , 2026. Solid plans to meet with the FDA late in the fourth quarter of 2026 to discuss the INSPIRE DUCHENNE SGT - 003 data package and to seek guidance on a potential accelerated approval pathway for SGT - 003 ; the Company expects to provide an update as discussions progress . • As announced on May 7 , 2026 , the Company reported that the first participant was dosed in the Phase 3 IMPACT DUCHENNE placebo - controlled , randomized , double - blind clinical trial . Clinical sites are currently active in Australia and Canada , with additional clinical site activations expected in the second half of 2026 , subject to site initiation activities and regulatory clearances . SGT - 212 for Friedreich's ataxia ( FA ) • SGT - 212 has been well tolerated , with no treatment - related serious adverse events ( TRSAEs ) observed in the two participants dosed in the Phase 1b FALCON clinical trial as of August 4 , 2026 . Participant screening and enrollment remains ongoing , and the Company expects to report initial data in the first quarter of 2027 , subject to participant enrollment .